Sutro BiopharmaSTRO
About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Employees: 269
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
30% more call options, than puts
Call options by funds: $35K | Put options by funds: $27K
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
3.87% less ownership
Funds ownership: 77.49% [Q4 2024] → 73.62% (-3.87%) [Q1 2025]
7% less funds holding
Funds holding: 123 [Q4 2024] → 114 (-9) [Q1 2025]
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
66% less capital invested
Capital invested by funds: $118M [Q4 2024] → $40.1M (-$77.4M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
B of A Securities Tazeen Ahmad | 0%upside $0.80 | Underperform Maintained | 19 May 2025 |
HC Wainwright & Co. Andres Maldonado | 150%upside $2 | Neutral Reiterated | 29 Apr 2025 |
HC Wainwright & Co. Andrew Fein | 150%upside $2 | Neutral Downgraded | 17 Mar 2025 |
Financial journalist opinion
